Primary upper-extremity deep vein thrombosis: high prevalence of thrombophilic defects.
Primary deep venous thrombosis of the upper extremity (UEDVT) is an unusual disorder. Limited data are available on the contribution of hypercoagulable status in the pathogenesis of this disease. This study aims to report the prevalence of inherited and acquired thrombophilic risk factors (TF) in patients with primary (effort-related and spontaneous) UEDVT. From 1993 to 2002, 31 patients (17 females, median age 38.8 years, range 16-60 years; and 14 males, median age 31.4 years, range 20-56 years) with primary UEDVT (n = 15 effort-related and n = 16 spontaneous) were referred for screening of hypercoagulable status. Nineteen (61.3%) patients had at least one coagulation abnormality. The most common acquired TF were antiphospholipid antibodies (31% lupus anticoagulant and 12.9% anticardiolipin antibodies). Factor V Leiden (12.9%) and prothrombin G20210A mutation (20%) were the most prevalent genetic risk factors. Five patients (16.1%) had high plasma homocysteine levels, and one patient (4.7%) had protein S deficiency. Effort-related UEDVT was associated with male gender (P = 0.04) and younger age (P = 0.02). There was no significant difference in the prevalence of acquired or inherited TF between patients with effort-related or spontaneous UEDVT. A local anatomic abnormality was detected in seven patients (22.5%), and the prevalence of TF was significantly lower within this group (P = 0.006). The incidence of TF in patients without an anatomic abnormality was 75% (RR 5.25). This study found a high prevalence of an underlying thrombophilic status in spontaneous and effort-related UEDVT. Hypercoagulable status may play a significant role in both groups. Screening for local anatomical abnormalities and thrombophilia should be included in the evaluation of primary UEDVT.
Hendler
Mariela F
MF
Departamento de Hemostasia y Trombosis, Instituto de Investigaciones Hematológicas Mariano R. Castex, Academia Nacional de Medicina de Buenos Aires, Buenos Aires, Argentina. hendler@hematologia.anm.edu.ar
Meschengieser
Susana S
SS
Blanco
Alicia N
AN
Alberto
Maria F
MF
Salviú
Maria J
MJ
Gennari
Laura
L
Lazzari
Maria A
MA
D020413:3' Untranslated Regions; D020016:Activated Protein C Resistance / Q000150:complications / Q000453:epidemiology / Q000235:genetics; D000293:Adolescent; D000328:Adult; D017153:Antibodies, Anticardiolipin / Q000097:blood; D016736:Antiphospholipid Syndrome / Q000097:blood / Q000150:complications / Q000453:epidemiology; D001118:Argentina / Q000453:epidemiology; D001132:Arm; D002574:Cervical Vertebrae / Q000002:abnormalities; D005165:Factor V / Q000235:genetics; D005260:Female; D006801:Humans; D020138:Hyperhomocysteinemia / Q000150:complications / Q000453:epidemiology; D016682:Lupus Coagulation Inhibitor / Q000097:blood; D008297:Male; D008875:Middle Aged; D005082:Physical Exertion; D015995:Prevalence; D018455:Protein S Deficiency / Q000150:complications / Q000453:epidemiology; D011516:Prothrombin / Q000235:genetics; D012189:Retrospective Studies; D012307:Risk Factors; D013348:Subclavian Artery / Q000002:abnormalities; D019851:Thrombophilia / Q000150:complications / Q000453:epidemiology* / Q000235:genetics; D020246:Venous Thrombosis / Q000097:blood / Q000453:epidemiology / Q000209:etiology* / Q000473:pathology
D020413:3' Untranslated Regions; D017153:Antibodies, Anticardiolipin; D016682:Lupus Coagulation Inhibitor; C095381:factor V Leiden; D005165:Factor V; D011516:Prothrombin